A March 2026 study from Washington University School of Medicine, published in BMJ Medicine, found that stopping GLP-1 medications can rapidly erase those cardiac benefits
Centrally administered GLP-1 analogue improves intestinal barrier function through the brain orexin and the vagal pathway in rats
The class of drugs called GLP-1 (glucagon-like peptide-1) agonists stimulates a hormone that occurs in the body naturally
D., Gill, S., Eichhoff, O
A cross-sectional study in women found that low levels of IGF-1 were associated with poor knee extensor muscle strength, slow walking speed, and difficulty with mobility tasks [1]
Lower doses still produce excellent weight loss results with reduced side effects